These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 18245410)

  • 21. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.
    Sohn YB; Choi EW; Kim SJ; Park SW; Kim SH; Cho SY; Jeong SI; Huh J; Kang IS; Lee HJ; Paik KH; Jin DK
    Am J Med Genet A; 2012 Jan; 158A(1):90-6. PubMed ID: 22105882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry].
    del Toro-Riera M
    Rev Neurol; 2007 Feb; 44 Suppl 1():S13-7. PubMed ID: 17345554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations.
    Kim CH; Hwang HZ; Song SM; Paik KH; Kwon EK; Moon KB; Yoon JH; Han CK; Jin DK
    Hum Mutat; 2003 Apr; 21(4):449-50. PubMed ID: 12655569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial report from the Hunter Outcome Survey.
    Wraith JE; Beck M; Giugliani R; Clarke J; Martin R; Muenzer J;
    Genet Med; 2008 Jul; 10(7):508-16. PubMed ID: 18580692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.
    D'Avanzo F; Rigon L; Zanetti A; Tomanin R
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).
    Peters C; Krivit W
    Bone Marrow Transplant; 2000 May; 25(10):1097-9. PubMed ID: 10828872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
    Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
    J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele.
    Sukegawa K; Song XQ; Masuno M; Fukao T; Shimozawa N; Fukuda S; Isogai K; Nishio H; Matsuo M; Tomatsu S; Kondo N; Orii T
    Hum Mutat; 1997; 10(5):361-7. PubMed ID: 9375851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucopolysaccharidosis Type II and the G374sp Mutation.
    Martínez-Quintana E; Rodríguez-González F
    Mol Syndromol; 2013 Apr; 4(4):203-6. PubMed ID: 23801937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucopolysaccharidosis type II, Hunter's syndrome.
    Tylki-Szymańska A
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).
    Garcia AR; Pan J; Lamsa JC; Muenzer J
    J Inherit Metab Dis; 2007 Nov; 30(6):924-34. PubMed ID: 17876721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin type A for the treatment of equinus deformity in patients with mucopolysaccharidosis type II.
    Nava E; Weber P; Gautschi M; Nuoffer JM; Grunt S
    J Child Neurol; 2012 Dec; 27(12):1611-5. PubMed ID: 22433425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.
    Chiong MA; Canson DM; Abacan MA; Baluyot MM; Cordero CP; Silao CL
    Orphanet J Rare Dis; 2017 Jan; 12(1):7. PubMed ID: 28077157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mucopolysaccharidosis type II (Hunter syndrome)].
    Sukegawa K; Tomatsu S; Kondo N; Orii T
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):435-8. PubMed ID: 9645102
    [No Abstract]   [Full Text] [Related]  

  • 39. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment.
    Mohamed S; He QQ; Singh AA; Ferro V
    Adv Carbohydr Chem Biochem; 2020; 77():71-117. PubMed ID: 33004112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mother and daughter with the p.R443X mutation of mucopolysaccharidosis type II: Genotype and phenotype analysis.
    Sohn YB; Kim SJ; Park SW; Park HD; Ki CS; Kim CH; Huh SW; Yeau S; Paik KH; Jin DK
    Am J Med Genet A; 2010 Dec; 152A(12):3129-32. PubMed ID: 21108396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.